Arvinas price target lowered to $12 from $48 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Arvinas (ARVN) to $12 from $48 and keeps an Equal Weight rating on the shares after the ...
Novel antibody reduces tumor growth in treatment-resistant breast and ovarian cancers
Antibody treatment which activates the patient's own immune system against cancer, known as immunotherapy, is increasingly ...
PharmExec3h
Phase III Trial Data Show Vepdegestrant Produces Encouraging Outcomes in ER+/HER2- Advanced or Metastatic Breast Cancer
Topline results from the Phase III VERITAC-2 trial found that vepdegestrant provided a statistically significant and clinically meaningful improvement in progression-free survival in patients with ER+ ...
Novel radiotracer identifies biomarker for triple-negative breast cancer
A new PET radiotracer can effectively visualize Nectin-4, an emerging biomarker found in triple-negative breast cancer (TNBC) ...
Arvinas draws Wedbush downgrade after data for Pfizer-partnered cancer drug
Arvinas (ARVN) stock faces a downgrade after underwhelming trial data for breast cancer drug vepdegestrant developed with ...
PipelineReview.com22h
Arvinas and Pfizer Announce Positive Topline Results from Phase 3 VERITAC-2 Clinical Trial
VERITAC-2 achieved its primary endpoint in the estrogen receptor 1-mutant population, demonstrating statistically significant and clinically meaningful ...
ARVN Stock Plunges 53% Following Mixed Data From Breast Cancer Study
Arvinas stock plummets 53% on mixed data from phase III metastatic breast cancer study on lead pipeline candidate, vepdegestrant.